Markets:

Overview

News

Currencies

International

Treasuries

Longeveron Inc. - Class A Common stock (NQ:LGVN)

0.7591 -0.0111 (-1.44%)

Streaming Delayed Price Updated: 1:02 PM EDT, Jun 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Longeveron Inc. - Class A Common stock

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

Earnings Scheduled For August 13, 2021 ↗

August 13, 2021

Companies Reporting Before The Bell • Jaguar Health (NASDAQ:JAGX) is expected to report quarterly loss at $0.03 per share on revenue of $7.28 million. • Fangdd...

Via Benzinga

The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More ↗

July 25, 2021

Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start...

Via Benzinga

Longeveron's Founders Hopeful That With Continued Clinical Trial Success, Lomecel-B May Win Regulatory Approval ↗

July 07, 2021

Longeveron Inc. (NASDAQ: LGVN) is optimistic it could receive regulatory approvals in different countries for its lead regenerative medicine product Lomecel-B (cell-based...

Via Benzinga

Longeveron, Armed with Positive Results of Phase I Clinical Study of Lomecel-B Cell Therapy for Alzheimer's Disease, Presenting at AAIC & Headed to Phase 2 Trials ↗

June 28, 2021

Longeveron CEO Geoff Green presented at the Benzinga Global Small Cap Conference held on May 13-14, 2021. In addition to sharing the company’s corporate outlook, Green...

Via Benzinga

Alzheimer’s Treatment Market Is Anticipated To Reach $2 Billion By The End Of 2027

June 24, 2021

Via FinancialNewsMedia

Topics Death

Longeveron Announces Abstract Highlighting Data from Phase 1 Alzheimer's Disease Trial Accepted for Developing Topics Presentation at the 2021 Annual Alzheimer's Association International Conference ↗

June 24, 2021

- Abstract presentation highlights safety and potential efficacy of Lomecel-B infusion in patients with mild Alzheimer’s Disease - Miami, Florida – June 24th, 2021 -...

Via Benzinga

48 Biggest Movers From Friday ↗

May 24, 2021

Gainers Annovis Bio, Inc. (NASDAQ: ANVS) shares surged 127.3% to close at $60.00 on Friday after the company announced new results from a Phase 2 study evaluating its lead drug...

Via Benzinga

30 Stocks Moving In Friday's Mid-Day Session ↗

May 21, 2021

Gainers Annovis Bio, Inc. (NASDAQ: ANVS) shares jumped 105.4% to $54.23 after the company announced new results from a Phase 2 study evaluating its lead drug candidate, ANVS401,...

Via Benzinga

The Promise Of Longevity Science: 3 Small-Cap Companies With Anti-Aging Products ↗

May 14, 2021

The challenge in securing a longer and healthier life was the focus of “Investing in Longevity Science: The New Drugs & Therapies Designed to Prolong Your Lifespan,...

Via Benzinga

Earnings Scheduled For May 14, 2021 ↗

May 14, 2021

Companies Reporting Before The Bell • Sogou (NYSE:SOGO) is projected to report earnings for its first quarter. • Sohu.com (NASDAQ:SOHU) is estimated to report...

Via Benzinga

34 Stocks Moving In Tuesday's Mid-Day Session ↗

April 13, 2021

Gainers Mackinac Financial Corporation (NASDAQ: MFNC) jumped 57.6% to $20.75 after the company, and Nicolet Bankshares, jointly announced the execution of a definitive merger...

Via Benzinga

The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts ↗

May 14, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13) Alexion Pharmaceuticals, Inc...

Via Benzinga

The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use ↗

May 13, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12) Alexion Pharmaceuticals, Inc...

Via Benzinga

The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs ↗

May 07, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6) GT Biopharma, Inc. (NASDAQ:...

Via Benzinga

The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs ↗

April 22, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 21) Alexion Pharmaceuticals,...

Via Benzinga

SmallCapsDaily: Longeveron Inc. Emerges as a True Blue Bio-Tech Titan

April 12, 2021

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

50 Biggest Movers From Yesterday ↗

April 14, 2021

Gainers Mackinac Financial Corporation (NASDAQ: MFNC) shares surged 60.7% to close at $21.16 on Tuesday after the company, and Nicolet Bankshares, jointly announced the execution...

Via Benzinga

SmallCapsDaily: Longeveron Inc. Emerges as a True Blue Bio-Tech Titan

April 12, 2021

New York, New York--(Newsfile Corp. - April 12, 2021) - Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage...

Via Newsfile

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Longeveron Inc. - Class A Common stock (NQ:LGVN)

All News about Longeveron Inc. - Class A Common stock

Resources